ライフサイエンスコーパス: mannoside

1 olic instability of the O-glycosidic bond (O-mannosides).

2 contact with distal portions of the branched mannoside.

3 . coli ORN 208, which does not bind to alpha-mannoside.

4 E. coli ORN 178, which is specific for alpha-mannoside.

5 e axial 2-OH group of a (4)C(1) ground state mannoside.

6 t installation of the galactose beta-(1-->4) mannoside.

7 harmacokinetic (PK) properties relative to O-mannosides.

8 IGN binds more efficiently to densely packed mannosides.

9 er levels of binding to phosphatidylinositol mannosides.

10 in a novel detergent system employing alkyl mannosides.

11 ations being the addition of O- and N-linked mannosides.

12 d the higher-order phosphatidyl-myo-inositol mannosides.

13 high alpha-selectivities were the norm for C-mannosides.

14 dified allylsilane 29a-c to C(2)OH of methyl mannoside 15 improved matters.

15 Methyl mannoside 16 containing an allyldimethylsilyl ether at C

16 Reaction of the tethered mannosides 27a-c with TMSOTf in the presence of 2,6-DTBM

17 n peptidoglycan (mAGP), phosphatidylinositol mannoside-6 (PIM6) and lipomannan (LM) were identified a

18 the carboxylate substituted biphenyl alpha-d-mannoside 9, affinity and the relevant pharmacokinetic p

19 T2) are able to interact with four different mannoside acetylglucosaminyltransferases (Mgat1, Mgat2,

20 macrophages were treated with alpha-methyl-D-mannoside (alphaMM), a competitor of glycopeptide ligand

21 y gave a mixture of the desired alpha-linked mannoside and an orthoacetate resulting from attack at t

22 colipids, specifically, phosphatidylinositol mannoside and mannose-capped lipoarabinomannan, were pot

23 ed products such as the phosphatidylinositol mannosides and linear and mature branched lipomannan and

24 ria or by millimolar concentrations of alpha-mannosides and micromolar concentrations of high-mannose

25 on of higher order phosphatidyl-myo-inositol mannosides and the presence of dimycocerosates, triglyce

26 The stereoselective synthesis of beta-mannosides and the underlying reaction mechanism have be

27 ens, lipoarabinomannan, phosphatidylinositol mannoside, and glucose monomycolate.

28 synthetic substrate, 4-umbelliferyl-alpha-D-mannoside, and this activity is inhibited by swainsonine

29 trehalose dimycolates, phosphatidylinositol mannosides, and highly apolar lipids, similar to the Min

30 ion at the hindered anomeric center of alpha-mannosides, and the potential of mannosidase inhibitors

31 This new class of C-mannoside antagonists have significantly increased compo

32 followed by lipomannan, phosphatidylinositol mannoside, arabinosyl-lipoarabinomannan, and dimycolated

33 with Raney nickel, the so-formed 6-thio-beta-mannosides are converted in high yield to the beta-rhamn

34 strategy in which properly protected phospho-mannosides are coupled with a Fmoc protected threonine d

35 The observation that 1-thio-linked mannosides are not well tolerated by the catalytic site

36 On addition of an acceptor alcohol alpha-mannosides are then formed.

37 one- or p-nitrophenol-linked) alpha- or beta-mannosides as substrates indicated that there was no cor

38 ucomannan by cleaving the glycosidic bond of mannosides at the -1 subsite.

39 glycans is UDP-N-acetylglucosamine:alpha-3-D-mannoside beta-1,2-N-acetylglucosaminyltransferase I (Gl

40 the Mgat2 gene encoding UDP-GlcNAc:alpha-6-d-mannoside beta-1,2-N-acetylglucosaminyltransferase II en

41 albicans cell wall expresses beta-1,2-linked mannosides (beta-Mans), promoting its adherence to host

42 lvement of UDP-N-acetylglucosamine:alpha-6-D-mannoside beta1,6-N-acetylglucosaminyltransferase V (MGA

43 Golgi apparatus resident UDP-GlcNAc:alpha3-D-mannoside beta1-2-N-acetylglucosaminyltransferase I acti

44 ylation requires MGAT1 (UDP-GlcNAc:alpha-3-D-mannoside-beta1,2-N-acetylglucosaminyl-transferase I) fu

45 ed to govern the affinity and specificity of mannoside binding, we characterized the FimHL Y48A mutan

46 cross-talk between allosteric sites and the mannoside-binding pocket.

47 ivity toward the simple sugar alpha-methyl d-mannoside but impaired phosphorylation of acid hydrolase

48 es was inhibited by mannose and alpha-methyl mannoside but not by EDTA or arginine.

49 y suppressed in the presence of alpha-methyl-mannoside but not in the presence of mannose 6-phosphate

50 tively depleting intestinal UPEC reservoirs, mannosides could markedly reduce the rate of UTIs and re

51 ibited the synthesis of phosphatidylinositol mannosides, early precursors to LAM.

52 inide component from the corresponding alpha-mannoside employed Deshong's novel azide displacement pr

53 ture-based design and optimization of biaryl mannoside FimH inhibitors.

54 acylglycerol and cholesteryl 6'-O-acyl alpha-mannoside, found in Saccharopolyspora and Candida albica

55 prepared with terminal hydroxyl, methoxy, or mannoside functionality and incorporated into nanocarrie

56 ed, and especially the benzylidene-protected mannosides have gained a lot of attention since the corr

57 The lead mannosides have increased metabolic stability and oral b

58 Conformational analysis of enzyme-catalyzed mannoside hydrolysis has revealed two predominant confor

59 sphere: Conformational analysis of enzymatic mannoside hydrolysis informs strategies for enzyme inhib

60 A key improvement is the use of alpha-methyl-mannoside in the purification buffers to overcome the ag

61 beta-selectivities (1:>10 alpha:beta) and C-mannosides in moderate alpha-selectivities (3:1 alpha:be

62 duced higher order phosphatidyl-myo-inositol mannosides in strains HN885 and HN1554 resulted in their

63 Mannosides in the southern hemisphere: Conformational an

64 s, this enzyme showed a preference for beta -mannosides including 1,4- beta -D-mannooligosaccharides,

65 ns in vivo and in vitro disclosed that alpha-mannosides induce BT3172 expression, which in turn induc

66 ggest that formation of both alpha- and beta-mannosides involve loose S(N)2-like transition-state str

67 and carba-beta-L-gulose from methyl alpha-D-mannoside is described.

68 nsition structure for formation of the alpha-mannoside is significantly looser.

69 Stereoselective synthesis of beta-mannosides is one of the most challenging linkages to ac

70 Two mannoside isomers differentiated Actinomyces israelii an

71 hieve stereocontrolled formation of the beta-mannoside linkage.

72 sual enzyme, endo-alpha-mannosidase, cleaves mannoside linkages internally within an N-linked glycan

73 evels of mycothiol, but phosphatidylinositol mannoside, lipomannan and lipoarabinomannan levels were

74 nthetic pathway of phosphatidyl-myo-inositol mannoside, lipomannan, and lipoarabinomannan, which are

75 nthetic pathway of phosphatidyl-myo-inositol mannosides, lipomannan, and lipoarabinomannan, which are

76 The normal spectrum of phosphatidylinositol mannosides, long presumed precursors of these lipoglycan

77 Oral delivery of BSA bearing 51 molecules of mannoside (Man(51)-BSA) substantially reduced the BSA-in

78 f the binding site for the alpha(1,3)-linked mannoside of the natural substrate.

79 -alpha-D-mannopyr anoside both provide alpha-mannosides on activation with benzenesulfenyl triflate f

80 nic organisms that display alpha(1-2)-linked mannosides on their cell surfaces suggests a broad defen

81 coproteins and also whole cells that display mannosides on their surface.

82 alpha-Mannoside or beta-galactoside was immobilized on a gold

83 Substitution on the mannoside phenyl ring ortho to the glycosidic bond resul

84 is of the substrate specificity of UhgbMP, a mannoside phosphorylase of the GH130 protein family disc

85 ive site mannose are conserved in both GH130 mannoside phosphorylases and beta-1,2-mannosidases.

86 data demonstrating that phosphatidylinositol mannoside (PIM) specifically stimulated homotypic fusion

87 s cell wall glycolipid, phosphatidylinositol mannoside (PIM), induces homotypic adhesion of human CD4

88 Phosphatidyl-inositol mannosides (PIM) are glycolipids unique to mycobacteria

89 Phosphatidylinositol mannosides (PIM), lipomannan (LM), and lipoarabinomannan

90 Phosphatidyl-myo-inositol mannosides (PIMs) are key glycolipids of the mycobacteri

91 of LAM, lipomannan, and phosphatidylinositol mannosides (PIMs) compared with control strains and led

92 ocessed to give rise to phosphatidylinositol mannosides (PIMs) or lipoarabinomannan.

93 mannosylated with phosphatidyl-myo-inositol mannosides (PIMs), lipomannan, and mannose-capped lipoar

94 he biosynthesis of phosphatidyl-myo-inositol mannosides (PIMs), which are key components of the mycob

95 s of mycobacterial phosphatidyl-myo-inositol mannosides (PIMs).

96 obably originate in the phosphatidylinositol mannosides (PIMs; PIMans).

97 Using arrays of mannoside-presenting SAMs, inhibitors of bacterial adhes

98 FimH with M4284, a high-affinity inhibitory mannoside, reduces intestinal colonization of geneticall

99 ion after exposure to acidic conditions, and mannoside resulted in only 32% inhibition of uptake by m

100 treatment of macrophages with alpha-methyl-D-mannoside significantly reduced the cytokine GM-CSF resp

101 enzyme inhibition and inspires solutions to mannoside synthesis.

102 investigated using nanocarriers having 0-75% mannoside-terminated PEG chains in the PEG corona.

103 nanocarrier association is attained with 9% mannoside-terminated PEG chains, increasing uptake more

104 significantly higher in the case of the beta-mannoside than of the beta-xyloside.

105 ed in part through phosphatidyl-myo-inositol mannosides that are present in the cell wall of both rou

106 this promising new class of carbon-linked C-mannosides that show improved pharmacokinetic (PK) prope

107 se all reported FimH antagonists are alpha-d-mannosides, they are also potential ligands of mannose r

108 that the conformational change of the bound mannoside to a high-energy B 2,5 conformation is facilit

109 led unambiguous distortion of the -1 subsite mannoside to an (O)S2 conformation, matching that predic

110 g anti-CD11b receptor blocking antibodies or mannoside to inhibit the uptake of M. tuberculosis by ma

111 We developed a set of mannosides to prevent AIEC attachment to the gut by bloc

112 differ in their ability to recognize various mannosides, utilizing at least two different mechanisms.

113 st potent representative, an indolinylphenyl mannoside, was administered in a mouse model at the low

114 e physical and pharmacokinetic properties of mannosides were assessed for FimH binding affinity based

115 No species degraded these alpha-linked mannosides, while degradation of the beta-linked synthet